• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Transdermal buprenorphine effective for moderate-to-severe chronic low back pain

News
Article

Transdermal buprenorphine (Butrans Transdermal System, Purdue Pharma) was superior to placebo in treating opioid-naïve patients with moderate-to-severe chronic low back pain, according to study results presented at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.

Transdermal buprenorphine (Butrans Transdermal System, Purdue Pharma) was superior to placebo in treating opioid-naïve patients with moderate-to-severe  chronic low back pain, according to study results presented at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.

For this randomized, double-blind, placebo-controlled, parallel-group study, researchers included patients aged ≥18 years with moderate-to-severe low back pain for a minimum of 3 months prior to study entry. Using an enrichment design, researchers treated patients after the screening period with open-label buprenorphine during the run-in period (n=1,024), and then randomly assigned them to treatment with buprenorphine (10 µg or 20 µg; n=257) or matching placebo (n=284).

Week 12 average pain scores (APS) were statistically significantly better in the buprenorphine group compared with placebo (APS=-0.58; P=.0104). Greater proportions of patients with ≥30% and ≥50% pain score improvements were seen in the buprenorphine group.

A secondary end point in the study was the comparison of Medical Outcomes Study (MOS)-sleep disturbance subscale scores, which showed a statistically significant difference in favor of the buprenorphine group (P=.0062). The most common adverse events were nausea, application site rash, and headache.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.